

6th August 2015

ASX ANNOUNCEMENT

ANALYTICA SUCCESSFULLY COMPLETES RIGHTS ISSUE

Analytica Limited (**Company**) is pleased to announce the successful completion of its partially-underwritten 1 for 2 renounceable pro-rata rights issue (**Rights Issue**) announced on 8 July 2015.

227,164,628 shares were taken up under the Rights Issue (including applications for additional shares), which raised gross proceeds of \$1,817,317 at the offer price of 0.8c per new share.

The Rights Issue was undersubscribed by 242,445,222 shares. Under the underwriting agreement, 122,835,372 shortfall shares will be taken up by investors introduced by the Underwriter (**Underwritten Shares**).

In accordance with the terms of the Rights Issue and the underwriting agreement, the Company will also grant:

- 116,166,666 short dated options exercisable at 1.1c on or before 29 February 2016; and
- 116,166,666 long dated option exercisable at 1.4c on or before 28 February 2018.

All shares issued and options granted are expected to be issued on or around Tuesday 11 August 2015 and expected to commence trading on Wednesday 12 August 2015 with the options granted quotation under ASX ticker codes ALTO (short dated options) and ALTOA (long dated options).

Bryan Dulhunty
Company Secretary

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1



in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. Product launches are anticipated in Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.